Vol.59 No.3 May 2011
Evaluation of S-1+Oxaliplatin+Bevacizumab combination chemotherapy in advanced colorectal cancer
Department of Oncology and Hematology, Edogawa Hospital, 2-24-18 Higashikoiwa, Edogawa-ku, Tokyo, Japan
Abstract
S-1, oxaliplatin and bevacizumab have been used as key drugs in the treatment of advanced colorectal cancer, but there has been no report on a safety of these three drugs (SOX+BV) as combination chemotherapy. In this report, we evaluated the safety of SOX+BV chemotherapy in 16 patients with advanced colorectal cancer. Bevacizumab (7.5 mg/kg) and oxaliplatin (130 mg/m2) were administrated intravenously on day 1, whereas S-1 was administrated orally (80 mg/m2/day, b.i.d.) for 14-days followed by a 7-day rest. The overall response rate was 87.5% (PR, 14 patients; SD, 2 patients) and disease control was 100% (16/16 patients). Bevacizumab-related side effects were observed in 10 patients (hypertension, 8 patients and 1 patient each with intestinal stoma leak and wound dehiscence at the port insertion site). S-1 related diarrhea was also observed in 5 patients, but it was manageable. In this study, SOX+BV chemotherapy demonstrated less toxicity, was cost-effective, and it seemed to have a non-inferior response rate and disease control compared with mFOLFOX6+BV. SOX+BV chemotherapy is an apparently valid choice for ambulatory chemotherapy. In future, further studies on SOX+BV chemotherapy, involving such factors as PFS, OS, and QOL, need to be addressed.
Key word
bevacizumab, S-1, oxaliplatin, advanced colorectal cancer
Received
March 3, 2011
Accepted
April 18, 2011
Jpn. J. Chemother. 59 (3): 302-307, 2011
